Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Operating Leases (2019 - 2025)

Beam Therapeutics (BEAM) has disclosed Operating Leases for 7 consecutive years, with $139.8 million as the latest value for Q4 2025.

  • Quarterly Operating Leases fell 5.54% to $139.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $139.8 million through Dec 2025, down 5.54% year-over-year, with the annual reading at $139.8 million for FY2025, 5.54% down from the prior year.
  • Operating Leases for Q4 2025 was $139.8 million at Beam Therapeutics, up from $138.7 million in the prior quarter.
  • The five-year high for Operating Leases was $168.6 million in Q4 2022, with the low at $125.8 million in Q1 2021.
  • Average Operating Leases over 5 years is $149.0 million, with a median of $148.5 million recorded in 2024.
  • The sharpest move saw Operating Leases surged 459.09% in 2021, then fell 7.48% in 2024.
  • Over 5 years, Operating Leases stood at $134.8 million in 2021, then increased by 25.08% to $168.6 million in 2022, then dropped by 5.17% to $159.9 million in 2023, then decreased by 7.48% to $148.0 million in 2024, then dropped by 5.54% to $139.8 million in 2025.
  • According to Business Quant data, Operating Leases over the past three periods came in at $139.8 million, $138.7 million, and $141.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.